Valuation: Hemostemix Inc.

Market Cap 10.88M 7.66M 6.7M 6.15M 5.74M 729M 11.05M 73.88M 28.72M 359M 28.75M 28.14M 1.24B P/E 2024
-4.36x
P/E 2025 -3.12x
Enterprise Value 13.74M 9.67M 8.46M 7.77M 7.24M 921M 13.95M 93.31M 36.27M 453M 36.31M 35.53M 1.56B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
82.24%
Yield 2024 *
-
Yield 2025 -
1 month-8.33%
3 months-21.43%
6 months-38.89%
Current year-38.89%
1 week 0.06
Extreme 0.055
0.06
1 month 0.05
Extreme 0.05
0.06
Current year 0.04
Extreme 0.04
0.11
1 year 0.04
Extreme 0.04
0.16
3 years 0.04
Extreme 0.035
0.42
5 years 0.04
Extreme 0.035
0.42
10 years 0
Extreme 0
5.9
Manager TitleAgeSince
Chief Executive Officer - 10/02/2020
Director of Finance/CFO - 05/03/2020
Chief Tech/Sci/R&D Officer - 14/10/2021
Director TitleAgeSince
Director/Board Member - 26/11/2019
Director/Board Member 67 09/02/2020
Director/Board Member - 08/04/2020
Date Insider Type Main position Quantity % Market Cap.
12-18Option

Director

65,000 0.0345%
12-16Option

Founder

242,000 0.1284%
12-16Buy

Founder

20,000 0.0106%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-60.71%-54.17% 7.66M
+0.68%+5.92%+80.45%+137.78% 59.1B
+2.32%+5.03%+75.51%+94.88% 55.19B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+45.58%-1.42% 19.69B
-0.29%+9.78%+44.62%-27.94% 17.56B
0.00%+20.78%+178.93%+360.74% 16.22B
+3.50%+1.97%+21.02%+191.95% 14.04B
+6.72%+19.38%+42.82% - 14.84B
Average +2.58%+7.71%+43.10%+125.57% 24.55B
Weighted average by Cap. +2.46%+6.47%+59.05%+137.70%

Financials

2024 2025
Net sales - -
Net income -2.62M -1.84M -1.61M -1.48M -1.38M -175M -2.66M -17.77M -6.91M -86.21M -6.91M -6.77M -297M -4.71M -3.32M -2.9M -2.67M -2.49M -316M -4.79M -32.01M -12.44M -155M -12.46M -12.19M -535M
Net Debt 4.23M 2.98M 2.6M 2.39M 2.23M 284M 4.3M 28.73M 11.17M 139M 11.18M 10.94M 480M 2.86M 2.01M 1.76M 1.62M 1.51M 192M 2.9M 19.43M 7.55M 94.27M 7.56M 7.4M 325M
Logo Hemostemix Inc.
Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patient’s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.
Employees
-
Date Price Change Volume
03/07/26 CA$0.0550 0.00% 1,000